Updated on 29 May 2014
Vancoplus is highly potent aganist bacteria-resistant infections like the MRSA, VRSA etc
Singapore: India's Chandigarh based Venus Remedies has bagged an additional patent for Vancoplus from USPTO. Vancoplus is an antibiotic adjuvant entity, effective against the deadly resistance of Methicillin Resistant Staphylococcus Aureus (MRSA). Developed by Venus Medicine Research Centre (VMRC), the R&D wing of Venus Remedies, Vancoplus is the only solution till date for MRSA with more than 9 percent success rate.
Quoting on the patent, Dr Manu Chaudhary, joint managing director, Venus Remedies said, "The patent is valid till 2032. We have already initiated the process for pre-IND meeting with USFDA, and we are quite optimistic about getting a fast track approval for this product as MRSA is under the list of limited pathogens, identified under GAIN act by FDA, and Vancoplus falls in the QIDP category."
Venus Remedies already has a product patent for Vancoplus from USPTO, this additional patent with broader coverage for use and method of treatment will be beneficial for the company. The formulation will be commercialized in the US market through technology transfer or outlicensing of exclusive marketing rights route.
Vancoplus is a novel antibiotic adjuvant entity, highly effective against MRSA, VISA, hGISA and mixed bacterial infections of gram negative and gram positive pathogens. It is the best and safest option to address such infections. It is also active against different mechanisms of resistance such as Cell Membrane impermeability, Efflux pumps, Biofilms, which no other therapeutic options available, are able to address.
It took Venus Medicine Research Centre (VMRC) more than seven years to develop this product, which has received an overwhelming response from the medical fraternity in India, since its launch in the country four years ago and is growing with more than 25 percent CAGR in the Indian market.